Overview

Efficacy and Safety of Prophylactic Treatment for Pneumocystis Jirovecii Pneumonia in Patients With Autoimmune Inflammatory Rheumatic Disease

Status:
RECRUITING

Trial end date:
2026-12-31

Target enrollment:

Participant gender:

Summary

This is an open-labeled, prospective clinical study aims at collecting and analyzing baseline characteristics of autoimmune inflammatory rheumatic disease (AIIRD) patients receiving sulfanilamide for preventive purposes, as well as subsequent follow-up data, in order to assess the efficacy and safety of the medication. Additionally, through a stratified analysis of risk factors, the investigators aim to identify the AIIRD population that would benefit most from preventive medication based on a favorable benefit-risk ratio.

Phase:

PHASE4

Details

Lead Sponsor:

Tongji Hospital

Treatments:

Trimethoprim, Sulfamethoxazole Drug Combination